Bank of New York Mellon
XENE icon

Bank of New York Mellon’s Xenon Pharmaceuticals XENE Stock Holding History

Bank of New York Mellon’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4M Buy
421,518
+25,380
+6% +$1.41M ﹤0.01% 1479
2026
Q1 		$23M Buy
396,138
+8,980
+2% +$414K ﹤0.01% 1459
2025
Q4 		$17.4M Sell
387,158
-31,258
-7% -$1.31M ﹤0.01% 1616
2025
Q3 		$16.8M Sell
418,416
-17,604
-4% -$620K ﹤0.01% 1634
2025
Q2 		$13.6M Buy
436,020
+184,873
+74% +$6.03M ﹤0.01% 1726
2025
Q1 		$8.43M Buy
251,147
+204,550
+439% +$7.77M ﹤0.01% 1937
2024
Q4 		$1.83M Sell
46,597
-2,294
-5% -$94.8K ﹤0.01% 2792
2024
Q3 		$1.92M Sell
48,891
-2,363
-5% -$95.3K ﹤0.01% 2758
2024
Q2 		$2M Sell
51,254
-15,656
-23% -$626K ﹤0.01% 2793
2024
Q1 		$2.88M Buy
66,910
+251
+0.4% +$11.5K ﹤0.01% 2575
2023
Q4 		$3.07M Sell
66,659
-100,690
-60% -$3.56M ﹤0.01% 2609
2023
Q3 		$5.72M Sell
167,349
-44,392
-21% -$1.66M ﹤0.01% 2243
2023
Q2 		$8.15M Buy
211,741
+12,354
+6% +$491K ﹤0.01% 2051
2023
Q1 		$7.14M Sell
199,387
-188,973
-49% -$6.98M ﹤0.01% 2108
2022
Q4 		$15.3M Sell
388,360
-49,285
-11% -$1.79M ﹤0.01% 1692
2022
Q3 		$15.8M Sell
437,645
-125,542
-22% -$4.51M ﹤0.01% 1634
2022
Q2 		$17.1M Sell
563,187
-16,021
-3% -$485K ﹤0.01% 1622
2022
Q1 		$17.7M Sell
579,208
-212,317
-27% -$6.36M ﹤0.01% 1743
2021
Q4 		$24.7M Sell
791,525
-143,118
-15% -$4.28M ﹤0.01% 1594
2021
Q3 		$14.3M Sell
934,643
-899
-0.1% -$15.6K ﹤0.01% 1921
2021
Q2 		$17.4M Sell
935,542
-22,611
-2% -$417K ﹤0.01% 1812
2021
Q1 		$17.2M Buy
958,153
+8,915
+0.9% +$151K ﹤0.01% 1789
2020
Q4 		$14.6M Buy
949,238
+202,435
+27% +$2.37M ﹤0.01% 1804
2020
Q3 		$8.27M Sell
746,803
-47,886
-6% -$563K ﹤0.01% 1955
2020
Q2 		$9.97M Buy
794,689
+118,813
+18% +$1.51M ﹤0.01% 1844
2020
Q1 		$7.66M Buy
675,876
+429,613
+174% +$6.12M ﹤0.01% 1848
2019
Q4 		$3.23M Sell
246,263
-3,987
-2% -$41.9K ﹤0.01% 2568
2019
Q3 		$2.25M Buy
250,250
+22,711
+10% +$215K ﹤0.01% 2685
2019
Q2 		$2.24M Buy
+227,539
New +$2.18M ﹤0.01% 2738

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Bank of New York Mellon's XENE Position: Q2 2026 in Review

Bank of New York Mellon increased its Xenon Pharmaceuticals (XENE) stake by 6.4% in Q2 2026, buying an estimated $1.41M and bringing the position to 421,518 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Bank of New York Mellon first reported a position in XENE in Q2 2019 and has held it in 29 quarters since. 120 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Bank of New York Mellon held 421,518 shares of Xenon Pharmaceuticals worth $25.4M as of Q2 2026.
  • Bank of New York Mellon bought 25,380 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.41M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1479 holding.
  • Bank of New York Mellon first reported a position in Xenon Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • 120 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.